Galapagos NV operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Galapagos NV with three other
companies in this sector in Belgium:
MDxHealth S.A.
(2017
sales of 35.56 million Euro [US$44.01 million]
),
argenx NV
(36.42 million Euro [US$45.07 million]
), and
Ablynx N.V.
(55.53 million Euro [US$68.73 million]
of which 100%
was Nanobodies).
Sales Analysis.
Galapagos NV reported sales of 155.92 million Euro (US$192.97 million)
for the
year ending
December of 2017.
This
represents
an
increase of 2.8%
versus 2016, when the company's sales were 151.61 million Euro.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Galapagos NV had sales
of 152.98 million Euro.
Sales of Fee-For-Services saw an increase
that was more than double the company's growth rate: sales were up
11.7% in 2017, from
7.90 million Euro to 8.83 million Euro.
Not all segments of Galapagos NV experienced an increase in sales in 2017:
sales of R&d fell 2.8% to 118.26 million Euro.